Telotristat Etiprate Patent Expiration
Telotristat Etiprate is used for treating carcinoid syndrome diarrhea in adults inadequately controlled by somatostatin analog therapy. It was first introduced by Tersera Therapeutics Llc
Telotristat Etiprate Patents
Given below is the list of patents protecting Telotristat Etiprate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Xermelo | US7709493 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Feb 28, 2031 | Tersera |
| Xermelo | US8193204 | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1- (4-chloro-2-(3-methyl-1H-pyrazol-1-YL)phenyl)2,2,2-trifluoroethoxy)-pyrimidin-4-YL)phenyl)propanoate and methods of their use | Feb 27, 2031 | Tersera |
| Xermelo | US8653094 | Solid forms of (S)-ethyl 2-amino-3-(4-(2-amino-6-((R)-1-(4-chloro-2-(3-methyl-1H-pyrazol-1-yl)phenyl)-2,2,2-trifluoroethoxy)-pyrimidin-4-yl)phenyl)propanoate and methods of their use | Dec 19, 2028 | Tersera |
| Xermelo | US7553840 | 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use | Dec 11, 2027 | Tersera |
| Xermelo | US7968559 | Methods of using 4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds | Dec 11, 2027 | Tersera |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Telotristat Etiprate's patents.
Latest Legal Activities on Telotristat Etiprate's Patents
Given below is the list recent legal activities going on the following patents of Telotristat Etiprate.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 22 Nov, 2023 | US8193204 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 14 Dec, 2022 | US7968559 |
| Mail Pub Notice re 312 amendment | 01 Mar, 2022 | US7709493 |
| Email Notification Critical | 01 Mar, 2022 | US7709493 |
| POST ISSUE OTHER COMMUNICATION TO APPLICANT- CERTIFICATE OF CORRECTION | 25 Feb, 2022 | US7709493 |
| Post Issue Communication - Certificate of Correction Denied | 25 Feb, 2022 | US7709493 |
| Patent Term Extension Certificate Critical | 06 Dec, 2021 | US7709493 |
| Change in Power of Attorney (May Include Associate POA) Critical | 27 Oct, 2021 | US8193204 |
| Email Notification Critical | 27 Oct, 2021 | US8193204 |
| Correspondence Address Change Critical | 25 Oct, 2021 | US8193204 |
Telotristat Etiprate's Family Patents
